Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$33.58 USD
+1.08 (3.32%)
Updated May 1, 2024 12:40 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AGIO 33.58 +1.08(3.32%)
Will AGIO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates
Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More
Other News for AGIO
Notable earnings before Thursday's open
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Director Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)